1. Home
  2. ENGN

as of 01-14-2026 10:46am EST

$8.94
+$0.55
+6.62%
Stocks Nasdaq

enGene Holdings Inc is a clinical-stage biotechnology company mainstreaming genetic medicine through the delivery of therapeutics to mucosal tissues and other organs, with the goal of creating new ways to address diseases with high clinical needs, beginning with non-muscle invasive bladder cancer (NMIBC). The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.

Founded: 1999 Country:
Canada
Canada
Employees: N/A City: SAINT-LAURENT
Market Cap: 605.5M IPO Year: N/A
Target Price: $22.71 AVG Volume (30 days): 202.6K
Analyst Decision: Buy Number of Analysts: 7
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -2.29 EPS Growth: N/A
52 Week Low/High: $2.65 - $11.14 Next Earning Date: 12-22-2025
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

AI-Powered ENGN Daily Prediction

Machine learning model trained on 25+ technical indicators

Updated 16 hours ago

AI Recommendation

hold
Model Accuracy: 76.47%
76.47%
Confidence

Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.

Share on Social Networks: